Get the Stockscreener App
0.00
100.00%
-5.11
Eliem Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
See More
Previous Close:
$5.11
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$342.68M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
0.00
EPS:
-1.69
Net Cash Flow:
$57,000
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$11.55
Eliem Therapeutics Inc Stock (ELYM) Company Profile
Name
Eliem Therapeutics Inc
Sector
Industry
Phone
877-354-3689
Address
2801 CENTERVILLE ROAD 1ST FLOOR, WILMINGTON
Eliem Therapeutics Inc Stock (ELYM) Latest News
How To Trade (CLYM) - Stock Traders Daily
Climb Bio to present kidney disease treatment study - Investing.com India
Climb Bio to present kidney disease treatment study By Investing.com - Investing.com UK
Eliem Therapeutics Inc [ELYM] Shares Fall -0.97 % on Wednesday - Knox Daily
Eliem Therapeutics rebrands to Climb Bio, shifts focus to immune diseases - Investing.com
Eliem Therapeutics Changes Name to Climb Bio - Yahoo Finance
Eliem Therapeutics to change corporate name to Climb Bio - TipRanks
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. - The Manila Times
Healthy Upside Potential: Eliem Therapeutics Inc (ELYM) - SETE News
Monitoring Eliem Therapeutics Inc (ELYM) after recent insider movements - Knox Daily
Eliem Therapeutics Inc (ELYM) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Ratio Analysis: Unpacking Eliem Therapeutics Inc (ELYM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Stock Position Decreased by Driehaus Capital Management LLC - MarketBeat
Selling Eliem Therapeutics Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m - Yahoo Finance
Eliem Therapeutics Inc (ELYM) can make a big difference with a little luck - SETE News
Eliem Therapeutics Inc (ELYM) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Affinity Asset Advisors LLC Takes $11.88 Million Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Trading (ELYM) With Integrated Risk Controls - Stock Traders Daily
500,000 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Acquired by Ally Bridge Group NY LLC - MarketBeat
Eliem Therapeutics: Recent Strategic Pipeline Restructuring (NASDAQ:ELYM) - Seeking Alpha
Closing Figures: Eliem Therapeutics Inc (ELYM)’s Positive Finish at 8.43, Up 1.81 - The Dwinnex
Eliem Therapeutics Inc (ELYM)’s stock price in review: A technical analysis - US Post News
Eliem therapeutics executive sells over $9,000 in company stock By Investing.com - Investing.com Australia
Eliem therapeutics executive sells over $9,000 in company stock - Investing.com
(ELYM) Trading Signals - Stock Traders Daily
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - GlobeNewswire
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 4.6% - MarketBeat
Eliem Therapeutics Inc [ELYM] Investment Appeal on the Rise - Knox Daily
ELYM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
A Guide To The Risks Of Investing In Eliem Therapeutics Inc (ELYM) - Knox Daily
Eliem Therapeutics appoints Kaplan as COO; Rampal as SVP, Clinical Development - MSN
Eliem Therapeutics announces executive changes, refocuses on autoimmune diseases - Investing.com India
Eliem Therapeutics: Executive Changes Amid Strategic Shift - TipRanks
Eliem Therapeutics expands executive team with new COO and SVP - Investing.com
Eliem Therapeutics appoints new COO Brett Kaplan - Investing.com
Eliem Therapeutics appoints new COO Brett Kaplan By Investing.com - Investing.com UK
Eliem Therapeutics Names Brett Kaplan as New COO - TipRanks
Eliem Therapeutics Announces Additions to its Leadership Team - GlobeNewswire
Eliem Therapeutics Announces Additions to its Leadership Team - GlobeNewswire Inc.
ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q2 2024 - MSN
(ELYM) Long Term Investment Analysis - Stock Traders Daily
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Up 34.0% in July - Defense World
Analyzing Eliem Therapeutics Inc (ELYM) After Recent Trading Activity - Knox Daily
Eliem Therapeutics Reports Second Quarter Financial Results - ForexTV.com
Sciatica Treatment Industry is Expected to Reach Rapid Growth - openPR
ELYM’s 2023 Market Dance: Up 124.07% – Time to Invest? - The InvestChronicle
Daily Progress: Eliem Therapeutics Inc (ELYM) Drop -15.50, Closing at 6.05 - The Dwinnex
Recent Insider Activity Could Benefit Eliem Therapeutics Inc (ELYM) - Knox Daily
How To Trade (ELYM) - Stock Traders Daily
Where are the Opportunities in (ELYM) - Stock Traders Daily
Eliem Therapeutics Inc Stock (ELYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eliem Therapeutics Inc Stock (ELYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morisset Valerie | EVP, R&D AND CSO |
Jul 22 '24 |
Sale |
8.03 |
69,005 |
554,170 |
31,317 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 19 '24 |
Sale |
7.21 |
60,201 |
434,325 |
100,322 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 18 '24 |
Sale |
6.93 |
38,576 |
267,332 |
160,523 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 17 '24 |
Sale |
6.91 |
3,207 |
22,160 |
199,099 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 16 '24 |
Sale |
7.13 |
50,000 |
356,500 |
202,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 12 '24 |
Sale |
7.07 |
50,000 |
353,500 |
294,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 15 '24 |
Sale |
7.01 |
42,377 |
297,063 |
252,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 11 '24 |
Sale |
7.11 |
50,000 |
355,500 |
344,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 10 '24 |
Sale |
6.83 |
50,000 |
341,500 |
394,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 09 '24 |
Sale |
6.66 |
5,931 |
39,500 |
444,683 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):